Brian Rini, MD, Chairs Session on Genitourinary Cancers

On May 18, Brian Rini, MD, Director of Cleveland Clinic Cancer Center’s Genitourinary Cancer Program, will chair one of five OncLive State of the Science Summits being held this year in cities across the U.S. His talk at the high-level session focused on genitourinary cancers is entitled “The Evolving Landscape of Adjuvant Therapy in Resected Localized Renal Cell Carcinoma” (RCC), and will cover important advances in the treatment of localized renal cell cancers. The Summits help community oncologists in diverse specialties stay current on the latest evidence-based treatment strategies for their patients.

Dr. Rini will discuss several large, ongoing randomized trials of targeted agents. He is staff in the Department of Solid Tumor Oncology and Professor of Medicine at Cleveland Clinic’s Lerner College of Medicine and an expert in antiangiogenic therapy and immunotherapy for RCC and prostate cancer. “This session will help participants make sense of what’s been learned so far, to inform their own calculation of the risk/benefit ratio involved with giving therapy in the adjuvant RCC setting,” says Dr. Rini. Each of the State of the Science Summits brings together academic and community-based physicians and healthcare professionals across key disciplines from medical and surgical oncology.

Other presenters will discuss:

• Immunotherapy approaches for renal cell carcinoma
• Immunotherapy for bladder cancer
• Active surveillance strategies for early prostate cancer
• Panel case discussions

Other Cleveland Clinic participants include Jorge Garcia, MD, of the Department of Hematology and Medical Oncology, Moshe Ornstein, MD, a Taussig Cancer Institute fellow, and Andrew Stephenson, MD, Director for the Center of Urologic Oncology at Cleveland Clinic’s Glickman Urological and Kidney Institute. The meeting will take place on Thursday, May 18, from 5:30-9 pm at the InterContinental Hotel in Cleveland.